Navigation Links
Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
Date:8/10/2009

PRINCETON, N.J., Aug. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended June 30, 2009.

Financial Results

Revenues were $10.5 million during the quarter ended June 30, 2009 compared to $0.5 million for the quarter ended June 30, 2008 and reflect the receipt of a $10.0 million milestone payment from Roche, following the initiation of the phase 2b study with RG7128, and the amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities was $5.8 million for the quarter ended June 30, 2009 as compared to $12.7 million for the quarter ended June 30, 2008. Pharmasset held $72.7 million in cash and cash equivalents at the end of the fiscal third quarter.

Total operating expenses for the quarter ended June 30, 2009 were $16.7 million as compared to $15.0 million for the same period in 2008. The increase in operating expenses for the quarter ended June 30, 2009 was primarily the result of an increase in clinical development expenses for PSI-7851, our second generation hepatitis C virus (HCV) product candidate, and preclinical development expenses for our purine series of compounds. Partially offsetting these increases were reduced expenses for our clevudine Phase 3 registration studies that were terminated during the quarter.

Pharmasset reported a net loss of $6.9 million, or $0.25 per share, for the quarter ended June 30, 2009, as compared to a net loss of $15.0 million, or $0.69 per share, for the quarter ended June 30, 2008.

Recent Highlights:

-- On July 31, 2009, Pharmasset announced positive preliminary results from a 3 day, multiple ascending dose trial with PSI-7851, a second generation, nucleotide analog inhibitor in HCV patients;

-- On July 7, 2009, Pharmasset announced the nomination of PSI-938 as a development candidate from two series of purine analogs for the treatment of chronic HCV infection. PSI-938 is a proprietary nucleotide analog polymerase inhibitor of HCV that is being advanced into studies required for submission of an Investigational New Drug (IND) application with the FDA or equivalent foreign regulatory application;

-- On June 9, 2009, Pharmasset announced that it had completed a single ascending dose trial with PSI-7851 and had begun dosing in a 3 day, multiple ascending dose trial in hepatitis C infected patients;

-- On April 25, 2009, Pharmasset announced positive results from the INFORM-1 study of the combination of RG7128 and another oral antiviral medicine, in the absence of interferon and ribavirin, for the treatment of HCV patients; and

-- In the third quarter, Pharmasset received a $10 million milestone from Roche following the initiation of the Phase 2b trial with RG7128, a first generation nucleoside prodrug for the treatment of hepatitis C.

"Pharmasset had another productive quarter, as we continued to make progress on all three of the nucleoside/tide analogs comprising our current portfolio of HCV product candidates", stated Schaefer Price, President and Chief Executive Officer. "We believe HCV therapy is evolving toward combinations of oral antiviral drugs. While we believe combinations of a nucleoside/tide with a drug having a different mechanism of action are very promising, we also believe combinations of two complementary nucleoside/tides have the potential for both a superior resistance profile and activity across all genotypes based on the in vitro evidence to date."

Calendar Year 2009 Anticipated Milestones:

-- Provide an update on safety from the first 100 patients in the Phase 2b trial of RG7128 in second half of 2009;

-- Report additional phase 1 antiviral data with PSI-7851 in second half of 2009;

-- Report further data from the INFORM-1 trial in fourth quarter of 2009.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM-1 studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical-stage candidates are PSI-7851, an unpartnered next generation HCV nucleotide analog which recently began Phase 1 clinical studies, and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys((R)) and Copegus((R) )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended June 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

                                PHARMASSET, INC.
          CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
                                   (UNAUDITED)


                          Three Months Ended          Nine Months Ended
                               June 30,                   June 30,
                      -------------------------   -------------------------
                            2009          2008          2009          2008
                      -----------   -----------   -----------   -----------
    REVENUES          $10,501,191      $464,291   $12,868,162    $1,392,874
                      -----------   -----------   -----------   -----------

    COSTS AND EXPENSES:
      Research and
       development     13,676,701    11,499,843    41,393,878    31,040,683
      General and
       administrative   2,995,566     3,473,635     9,958,441     9,902,453
                      -----------   -----------   -----------   -----------

        Total costs
         and expenses  16,672,267    14,973,478    51,352,319    40,943,136
                      -----------   -----------   -----------   -----------

    OPERATING LOSS     (6,171,076)  (14,509,187)  (38,484,157)  (39,550,262)

    INVESTMENT INCOME      37,729       216,287       204,938     1,697,737
    INTEREST EXPENSE     (815,764)     (735,543)   (2,417,498)   (1,484,880)
                      -----------   -----------   -----------   -----------

    LOSS BEFORE
     INCOME TAXES      (6,949,111)  (15,028,443)  (40,696,717)  (39,337,405)
    PROVISION FOR
     INCOME TAXES               -             -             -             -
                      -----------   -----------   -----------   -----------

    NET LOSS          $(6,949,111) $(15,028,443) $(40,696,717) $(39,337,405)
                      ===========  ============  ============  ============

    COMPREHENSIVE
     NET LOSS:
    NET LOSS          $(6,949,111) $(15,028,443) $(40,696,717) $(39,337,405)
    UNREALIZED GAIN
     (LOSS) ON
     AVAILABLE-FOR-
     SALE INVESTMENTS           -        12,503             -       (17,069)
                      -----------   -----------   -----------   -----------
    COMPREHENSIVE
     NET LOSS         $(6,949,111) $(15,015,940) $(40,696,717) $(39,354,474)
                      ===========  ============  ============  ============


    NET LOSS PER SHARE
      BASIC                $(0.25)       $(0.69)       $(1.57)       $(1.84)
      DILUTED              $(0.25)       $(0.69)       $(1.57)       $(1.84)

    WEIGHTED AVERAGE
     SHARES OUTSTANDING:
      BASIC            28,121,400    21,635,205    25,907,063    21,425,577
      DILUTED          28,121,400    21,635,205    25,907,063    21,425,577



                                PHARMASSET, INC.
                            CONDENSED BALANCE SHEET

                                                   As of          As of
                                                  June 30,     September 30,
                                                    2009           2008
                                                -----------    -----------
                                                (unaudited)
    ASSETS
    CURRENT ASSETS:
      Cash and cash equivalents                 $72,656,823    $63,073,103
      Short-term investments                              -        497,310
      Amounts due from collaboration partner        594,403      1,169,690
      Prepaid expenses and other assets           2,395,142      1,008,083
                                                  ---------      ---------
        Total current assets                     75,646,368     65,748,186
                                                 ----------     ----------

    EQUIPMENT AND LEASEHOLD IMPROVEMENTS:
      Laboratory, office furniture and equipment  3,563,147      3,362,846
      Leasehold improvements                      1,836,553      1,836,553
                                                  ---------      ---------
                                                  5,399,700      5,199,399
      Less accumulated depreciation and
       amortization                              (3,172,216)    (2,432,325)
                                                 ----------     ----------
        Total equipment and leasehold
         improvements, net                        2,227,484      2,767,074
    OTHER ASSETS                                    186,463        466,809
                                                    -------        -------
    TOTAL                                       $78,060,315    $68,982,069
                                                ===========    ===========

    LIABILITIES AND STOCKHOLDERS' EQUITY
    CURRENT LIABILITIES:
      Current portion of long-term debt          $7,011,558     $2,651,592
      Current portion of capital lease
       obligation                                         -         41,641
      Accounts payable                            2,188,714      2,466,052
      Accrued expenses                            7,978,083      6,182,417
      Deferred rent                                 111,164        124,463
      Deferred revenue                            1,857,136      1,857,136
                                                  ---------      ---------
        Total current liabilities                19,146,655     13,323,301

    DEFERRED RENT                                         -         79,793
    DEFERRED REVENUE                              2,476,091      3,868,965
    LONG-TERM DEBT, net                          14,277,488     16,522,665
                                                 ----------     ----------
        Total liabilities                        35,900,234     33,794,724
                                                 ----------     ----------

    COMMITMENTS AND CONTINGENCIES

    STOCKHOLDERS' EQUITY
    Common Stock, $0.001 par value,
     100,000,000 shares authorized, 28,139,902
     and 23,340,498 shares issued and
     outstanding at June 30, 2009 (unaudited)
     and September 30, 2008, respectively            28,140         23,340
    Warrants to purchase 127,248 and 116,183
     shares of common stock for $12.05 per
     share, as of June 30, 2009, (unaudited)
     and September 30, 2008, respectively         1,229,767      1,140,114
    Additional paid-in capital                  193,390,835    145,818,439
    Accumulated other comprehensive (loss)
     income                                               -         (2,604)
    Accumulated deficit                        (152,488,661)  (111,791,944)
                                               ------------   ------------
        Total stockholders' equity               42,160,081     35,187,345
                                                 ----------     ----------
    TOTAL                                       $78,060,315    $68,982,069
                                                ===========    ===========


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
2. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
3. Pharmasset to Present at Deutsche Bank Healthcare Conference
4. Pharmasset to Present at Two Upcoming Investor Conferences
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
7. Pharmasset to Webcast an Investor Event from the AASLD Meeting
8. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
9. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
10. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
11. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by environmental and ... with these stressors is to adopt a more healthful diet, but too many people ... a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... of our nation’s productivity, stability, even security. Most importantly, employees are the single ... Then why are American workers so unhappy? , Just under half of American ...
(Date:4/29/2016)... VA (PRWEB) , ... April 29, 2016 , ... ... with student loans more flexibility in repaying their loans, more information about their ... a time when total outstanding student loan debt, including federal and private loans, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Spine Team ... pain, is proud to announce one of their physicians has been invited to be ... Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016   Acsis , a leading provider of ... market research and advisory firm IDC has named it ... Worldwide Pharmaceutical Track and Trace Software 2016 Vendor Assessment ... assessment of the capabilities and business strategies of 10 ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
Breaking Medicine Technology: